实体瘤患者接受免疫检查点抑制剂后的ICU收治原因
这项在法国和比利时开展的前瞻性多中心研究纳入115例近6个月内接受系统性免疫检查点抑制剂治疗、非计划入住ICU的成人实体瘤患者,排除微生物学确诊脓毒症者。主要ICU入住原因为急性呼吸衰竭(57%)、结肠炎(13%)和心血管疾病(11%),入住ICU时与免疫相关不良事件关联性评为「很可能」者占48%(n=55)。独立相关因素包括ECOG体能状态评分0或1分(OR=6.34,95%CI 2.13-18.90)和2-3分(OR=3.66,95%CI 1.33-10.03),以及既往免疫相关不良事件史(OR=3.28,95%CI 1.19-9.01)。55例「很可能」相关患者中41例(75%)使用激素,3例后续接受免疫抑制剂治疗。
要点
- 实体瘤患者近6个月内接受免疫检查点抑制剂后非计划入住ICU,48%(55/115)归因于免疫相关不良事件。
- 主要ICU入住原因为急性呼吸衰竭(66/115,57%)、结肠炎(14/115,13%)和心血管疾病(13/115,11%)。
- 免疫相关不良事件独立相关因素:ECOG-PS 0或1分 vs 2-3分 OR=6.34(95%CI 2.13-18.90),ECOG-PS 2-3分 vs 0-1分 OR=3.66(95%CI 1.33-10.03),既往免疫相关不良事件史 OR=3.28(95%CI 1.19-9.01)。
- 55例「很可能」相关患者中41例(75%)使用激素,3例后续接受免疫抑制剂治疗。
- 研究排除微生物学确诊脓毒症患者,ICU入住时免疫相关不良事件归因判断仍具挑战。
适用人群与场景
- 成人实体瘤患者,近6个月内接受系统性免疫检查点抑制剂治疗,需非计划入住ICU。
- 排除因微生物学确诊脓毒症入住ICU的患者。
- 研究在法国和比利时的多中心开展。
诊断标准与关键阈值
- 免疫相关不良事件归因采用WHO-UMC分类系统,在ICU入住时和ICU转出时分别评估。
处置流程与药物剂量
- 55例ICU入住「很可能」与免疫相关不良事件相关的患者中,41例(75%)使用激素治疗。
- 3例后续接受免疫抑制剂治疗。
研究设计与关键结果
- 前瞻性多中心研究,纳入115例成人实体瘤患者,主要肿瘤类型为肺癌(n=76,66%)和黑色素瘤(n=18,16%),96%(n=110)单用抗PD-(L)1治疗。
- 主要ICU入住原因:急性呼吸衰竭(n=66,57%)、结肠炎(n=14,13%)、心血管疾病(n=13,11%)。
- 48%(n=55)患者ICU入住被认为「很可能」与免疫相关不良事件相关。
- 独立相关因素:ECOG-PS 0或1分 vs 2-3分 OR=6.34(95%CI 2.13-18.90);ECOG-PS 2-3分 vs 0-1分 OR=3.66(95%CI 1.33-10.03);既往免疫相关不良事件史 OR=3.28(95%CI 1.19-9.01)。
- 55例「很可能」相关患者中41例(75%)使用激素,3例后续接受免疫抑制剂治疗。
证据类型、等级与局限
- 证据类型:前瞻性多中心研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对近6个月内接受免疫检查点抑制剂的实体瘤患者入住ICU时,需将免疫相关不良事件纳入鉴别诊断,本研究中约一半ICU入住归因于此。
- ECOG-PS 0-1分和既往免疫相关不良事件史与ICU入住归因于免疫相关不良事件独立相关。
- 作者认为免疫相关不良事件可用激素治疗;识别ICU入住中免疫相关不良事件的归因仍是一个挑战。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Immune checkpoint inhibitors (ICI) have revolutionized the management of cancer. They can induce immune-related adverse events (irAE) leading to intensive care unit (ICU) admission. We aimed to describe irAEs for ICU admissions in solid cancer patients treated with ICIs.
METHODS: This prospective multicenter study was conducted in France and Belgium. Adult patients with solid tumor and treated with systemic ICIs within the last 6 months, requiring non-programmed ICU admission were included. Patients admitted for microbiologically documented sepsis were excluded. Imputability of irAEs in ICU admissions was described according to the WHO-UMC classification system at ICU admission and at ICU discharge. The use of immunosuppressant treatment was reported.
RESULTS: 115 patients were eligible. Solid tumor was mainly lung cancer (n = 76, 66%) and melanoma (n = 18, 16%). They were mainly treated with an anti-PD-(L)1 alone (n = 110, 96%). Main ICU admission reasons were acute respiratory failure (n = 66, 57%), colitis (n = 14, 13%), and cardiovascular disease (n = 13, 11%). ICU admission was considered "likely" associated with irAE for 48% (n = 55) of patients. Factors independently associated with irAE were a good ECOG performance status (PS) (ECOG-PS of 0 or 1 vs. ECOG-PS of 2-3, odds ratio [OR] = 6.34, 95% confidence interval [95% CI] 2.13-18.90, and OR = 3.66, 95% CI 1.33-10.03, respectively), and a history of irAE (OR = 3.28, 95% CI 1.19-9.01). Steroids were prescribed for 41/55 (75%) patients with ICU admission "likely" related to irAE. Three patients were subsequently treated with immunosuppressants.
CONCLUSION: IrAEs accounted for half of ICU admissions in cancer patients receiving ICIs. They could be treated with steroids. Identifying the imputability of irAEs in ICU admissions remains a challenge.
参考来源
- Toffart AC, Meert AP, Wallet F, et al. ICU admission for solid cancer patients treated with immune checkpoint inhibitors. Ann Intensive Care. 2023. PMID: 37072645. doi:10.1186/s13613-023-01122-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。